Neuvasq Biotechnologies
Neuvasq Biotechnologies is pioneering the development of first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies, designed to restore the integrity of the blood-retina and blood-brain barriers. This groundbreaking approach holds the potential to transform treatments and improve the lives of patients with vascular retinopathies – diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) – or severe neurological disorders.
7-day free trial · no credit card
Verified contacts
12
available on Kipplo
LinkedIn employees
15
1 to 10 range
Open roles
—
no listings
Distinct roles
7
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 12 verified contacts at Neuvasq Biotechnologies
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
12 contacts with verified email or phone · masked until revealed.
- MV
Marc Vanhove
Head Discovery · Research & Development
EmailPhone - SB
Stéphanie Buys
Executive Assistant Office Manager · General Business & Management
EmailPhone - IV
Isabel Vogel
Senior Scientist · Science
EmailPhone - MS
Margaux Silvestre
Scientist · Science
EmailPhone - ST
Sarah Thielens
Preclinical Research Associate · Science
EmailPhone - RL
Ralph Laufer
Chief Scientific Officer · Science
EmailPhone
Showing 6 of 12 verified contacts
Top roles at Neuvasq Biotechnologies
7 distinct titles indexed · top 7 shown.
- 2chief scientific officer
- 2scientist
- 1chief executive officer
- 1executive assistant office manager
- 1head discovery
- 1preclinical research associate
- 1senior scientist
Sign up to unlock all 12 contacts at Neuvasq Biotechnologies
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 12 verified contacts at Neuvasq Biotechnologies
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.